DPP-4 exists as a membrane-bound form, widely expressed and enzymatically active on numerous cell types and different vascular beds... ...as well as a soluble form ...
Dipeptidyl peptidase 4 (DPP-4; also known as CD26), a transmembrane receptor expressed on T cells, has a costimulatory function in activating T cells. In a mouse model, down-regulation of CD26 ...
Alogliptin (NESINA), a dipeptidyl peptidase IV (DPP-4) inhibitor, was approved by the FDA on January 25, 2013 to improve blood sugar control in adults with type 2 diabetes. This drug had been ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Fecal dipeptidyl peptidase-4 may be used as a ...
Study results have validated that five routinely measured clinical values reliably identified patients with type 2 diabetes who had significantly different A1c responses to two important classes of ...
Boehringer Ingelheim and Lilly announced preliminary data from the EMPRISE ( EMPagliflozin compaRative effectIveness and SafEty) real-world study at the Academy of Managed Care Pharmacy (AMCP) Annual ...
Merck & Co has scored its first regulatory approval for omarigliptin, a DPP-4 inhibitor for diabetes that need only be dosed once a week. Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) has ...
The results suggest that dipeptidyl peptidase-4 (DDP-4) inhibitors, which are widely prescribed in Germany, are not a cost-effective option despite lower drug pricing compared with empagliflozin.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback